Monday, 29 June 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 29 June 2026
News

$59M drug under threat

Posted 29 June 2026 AM

The TGA has approved Sanofi’s pegged blockbuster Altuviiio, Moderna’s latest Covid mRNA vaccine, plus the first generic versions of Ipsen’s Cabometyx and Takeda’s Revestive, both sponsored by Cipla.

Altuviiio, the first once-weekly factor VIII replacement intravenous infusion therapy for haemophilia A, made both Evaluate Vantage's analysis on new agents with blockbuster potential and Clarivate’s Drugs to Watch 2024 report, with the latter projecting the drug could earn US$1.77 billion in 2029.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (21)

Access & Reimbursement (2)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (6)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.